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Abstract
Background: In Her2-positive advanced breast cancer, the upfront use of trastuzumab is well established. Upon
progression on first-line therapy, patients may be switched to lapatinib. Others however remain candidates for continued
antibody treatment (treatment beyond progression). Here, we aimed to identify factors predicting for activity of second-
line trastuzumab-based therapy.
Methods: Ninety-seven patients treated with > 1 line of trastuzumab-containing therapy were available for this analysis.
Her2-status was determined by immunohistochemistry and re-analyzed by FISH if a score of 2+ was gained. Time to
progression (TTP) on second-line therapy was defined as primary study endpoint. TTP and overall survival (OS) were
estimated using the Kaplan-Meier product limit method. Multivariate analyses (Cox proportional hazards model,
multinomial logistic regression) were applied in order to identify factors associated with TTP, response, OS, and
incidence of brain metastases. p values < 0.05 were considered to indicate statistical significance.
Results: Median TTP on second-line trastuzumab-based therapy was 7 months (95% CI 5.74-8.26), and 8 months (95%
CI 6.25-9.74) on first-line, respectively (n.s.). In the multivariate models, none of the clinical or histopthological features
could reliably predict for activity of second-line trastuzumab-based treatment. OS was 43 months suggesting improved
survival in patients treated with trastuzumab in multiple-lines. A significant deterioration of cardiac function was observed
in three patients; 40.2% developed brain metastases while on second-line trastuzumab or thereafter.
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Conclusion:  Trastuzumab beyond progression showed considerable activity. None of the variables investigated
correlated with activity of second-line therapy. In order to predict for activity of second-line trastuzumab, it appears
necessary to evaluate factors known to confer trastuzumab-resistance.
Background
Human epidermal growth factor receptor (Her) 2 (c-erb-
B2) is a member of the Her-family of transmembrane
receptor proteins [1]. As no ligand has been identified,
Her2 is believed to act mainly via amplification of signals
from other members of the Her-family (EGFR, Her3,
Her4) by forming heterodimers [2]. Key proteins involved
in Her2 signal-transduction include phosphatidyl-inosi-
tol (PI) 3 kinase and the ras/raf cascade. Ultimately, acti-
vation of those signalling pathways results in changes of
growth, differentiation, adhesion, apoptosis and angio-
genesis [3]. Her2 is overexpressed in approximately 15 -
20% of breast cancer cases, and several studies have
shown that this confers a more aggressive course of dis-
ease [4,5].
Trastuzumab (rhMab4D5) is a recombinant monoclonal
humanized antibody targeting the extracellular domain of
Her2. Different mechanisms of action have been sug-
gested. Trastuzumab inhibits downstream signalling path-
ways and blocks the shedding of Her2's extracellular
domain. It causes internalization and degradation of the
Her2 receptor protein, cell cycle arrest due to decreased
cyclin-dependent kinase-2 (CDK2) activity via p27 induc-
tion, and inhibition of DNA repair. Antibody dependent
cellular cytotoxicity (ADCC) apparently also plays a role
[6,7]. In addition, trastuzumab may sensitize tumour cells
to the cytotoxic effects of conventional chemotherapy [8].
Phase II clinical trials established the activity of trastuzu-
mab as single-agent in Her2-positive metastatic breast
cancer [9,10]. Randomized studies proved the combina-
tion of trastuzumab and taxanes superior in terms of
response, progression-free and overall survival over chem-
otherapy alone [11,12]. Accordingly, trastuzumab was
approved as first-line treatment of Her2-positive meta-
static breast cancer in combination with taxanes. How-
ever, primary resistance may occur and many tumours
who have initial response to trastuzumab will acquire sec-
ondary resistance within one year. Trastuzumab resistance
is likely multi-factorial, and no clinical surrogate is yet
available [7].
Upon progression on trastuzumab-based first-line treat-
ment, two options exist. Patients may be switched to lap-
atinib, a tyrosine-kinase inhibitor of EGFR and Her2,
alternatively they may continue on trastuzumab in com-
bination with capecitabine. Up until recently the latter
approach was supported by data from retrospective anal-
yses, prospective observations, and a small phase II trial
only [13-15], while other studies questioned the potential
benefit of treatment beyond progression [16]. In the
meantime, a randomized phase III study reported results,
suggesting that trastuzumab in combination with capecit-
abine is more active than chemotherapy alone upon pro-
gression on trastuzumab-based first-line treatment in
terms of response rate and progression-free survival [17].
In contrast, in a large randomized phase III study, lapat-
inib plus capecitabine was active upon trastuzumab fail-
ure, and patients on lapatinib had a significantly lower
incidence of brain metastases [18].
As of now, there are no means to prospectively define the
optimal treatment approach for the individual patient.
Therefore, we aimed to identify factors predicting for effi-
cacy of trastuzumab treatment beyond disease progres-
sion. Furthermore, we tried to identify characteristics
associated with early development of brain metastases, as
this population will potentially benefit most from lapat-
inib.
Methods
All patient data were collected at the Department of Med-
icine 1 and Cancer Centre, Clinical Division of Oncology,
at the Medical University of Vienna, Vienna, Austria. This
retrospective analysis was performed in accordance with
the ethical regulations of the Medical University of
Vienna.
Patients
Ninety-seven consecutive patients treated from 2001 until
2008 with a minimum of two lines of trastuzumab-based
therapy for metastatic disease were available for this anal-
ysis. All patients were suffering from histologically con-
firmed Her2-positive advanced breast cancer as defined
per immunohistochemistry (IHC 3+) or fluorescence in-
situ hybridization (FISH +). For baseline staging evalua-
tions all patients had CT-scan of the chest and abdomen,
mammography, and gynaecologic examination. Before
initiation of trastuzumab treatment, echocardiography
was mandatory, and patients with left ventricular ejection
fraction (LVEF) below 50% were excluded.BMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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Treatment plan and patient evaluation
Trastuzumab was administered at a dose of 8 mg/kg body
weight loading dose on the first day of treatment, fol-
lowed by 6 mg/kg body weight every three weeks thereaf-
ter [19]. Re-evaluation of patients' tumour status was
performed every three cycles of treatment with CT-scan of
the chest and abdomen with additional work up if indi-
cated. Echocardiography was repeated every 6 months or
immediately if symptoms of congestive heart failure
occurred. If a significant LVEF drop (> 10%) was observed
but LVEF remained > 50%, those intervals were shortened
to every 4 weeks according to our institution standards
[20].
Statistical analysis
Time to disease progression (TTP) on the second trastuzu-
mab-based regimen for metastatic disease was defined as
primary study endpoint. Secondary endpoints consisted
of response rate, time to progression on first-line trastuzu-
mab-based therapy, cardiac toxicity, incidence of brain-
metastases, and overall survival (OS). TTP was defined as
the interval from the first day of treatment until docu-
mented tumour progression. If a patient died without
proper restaging, TTP was measured to the first day of clin-
ical deterioration. OS was defined as the interval from the
first day of trastuzumab application until death of any
cause.
According to UICC criteria, complete response (CR) was
defined as disappearance of all measurable lesions for a
minimum of eight weeks. Partial response (PR) was
defined as 25% or more reduction in sum of products of
the greatest diameters of measurable lesions, no increase
of lesion size and no new lesions. Stable disease (SD) was
defined as less than 25% decrease and less than 25%
increase without the appearance of new lesions. Progres-
sive disease (PD) was defined as greater than 25% increase
in tumour size or the appearance of new lesions.
TTP and OS were estimated using the Kaplan-Meier prod-
uct-limit method. To test for differences between TTP
curves, the log-rank test was used. p values less than 0.05
were considered to indicate statistical significance. In the
univariate analysis of TTP, the following variables were
included: age > 65 years; age < 35 years; tumour stage at
primary diagnosis (localized versus metastatic); grading
(1,2 versus 3); histological subtype (ductal versus lobular
carcinoma); hormone receptor status (oestrogen and/or
progesterone receptor positive versus negative); metastatic
sites (non-visceral only versus visceral involvement);
number of metastatic sites (1 versus ≥ 2; ≤ 2 versus > 2);
time to disease recurrence < 12 months following primary
treatment; trastuzumab from diagnosis of metastatic dis-
ease; response (CR + PR) to first-line trastuzumab treat-
ment; and appearance of new metastatic sites upon
progression on first-line trastuzumab. In the analysis of
factors predicting for OS, development of brain metas-
tases as well as early development of brain metastases (<
12 months after initiation of trastuzumab) were also
included.
A Cox proportional hazard model was applied as multi-
variate analysis to evaluate factors associated with OS and
TTP on second-line trastuzumab-based therapy. Variables
exhibiting significance (p < 0.05) or near significance (p <
0.08) at univariate analysis were included into the Cox
regression models. To evaluate variables associated with
treatment response to second-line trastuzumab-based
therapy as well as development of brain metastases, a
multinomial logistic regression model was used.
All statistics were calculated using statistical package for
the social sciences (SPSS®) 16.0 software (SPSS Inc., Chi-
cago, IL, USA). Data were analyzed as of February 2009.
Results
Patient characteristics
Ninety-seven consecutive patients, all female, suffering
from Her2-positive metastatic breast cancer were identi-
fied from a breast cancer database. Median age was 51
years, range 25-78 years. Table 1 lists the characteristics of
all patients included. 83.5% had invasive ductal carci-
noma; 42.3% had positive hormone receptor status, and
66% grade 3 tumours. Sixty-seven patients (69.1%) were
treated with adjuvant chemotherapy. Adjuvant endocrine
therapy was administered in 26 patients (26.8%), and a
further 9.3% received adjuvant trastuzumab for a median
duration of 10 months (range 4-24 months). Twenty-four
patients (24.7%) had metastatic disease at the time of pri-
mary diagnosis. Median time to disease recurrence in the
reminders was 24.5 months (range 4-210 months). In
75.3%, visceral metastases were present upon initiation of
palliative trastuzumab.
36.8% had received prior non-trastuzumab-containing
therapy for metastatic disease, and 14.4% were switched
to lapatinib after a median of four (range 2-9 lines) trastu-
zumab-based treatment lines.
Response and survival data
Follow-up data is available on all but one patient. Median
time of observation was 24 months (range 8-84 months).
Median TTP (second-line trastuzumab-based therapy)
was 7 months (95% CI 5.74-8.26), and 8 months (95% CI
6.25-9.74) on first-line trastuzumab-based therapy
respectively (n.s.). Clinical benefit rate (CBR) in the sec-
ond-line setting was 66% (CR 7.2%, PR 23.7%, SD > 6
months 35.1%), as compared to CBR 83.5% (CR 9.3%,
PR 35.1%, SD > 6 months 39.2%) on first-line. Efficacy
endpoints are summarized in Table 2.BMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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Patients with more than one metastatic site (TTP median
6 months [95% CI 5.06-6.98] versus 14 months [95% CI
9.56-18.44]; p = 0.013) as well as those with more than
two metastatic sites (TTP median 6 months [95% CI 5.09-
6.91] versus 8 months [95% CI 5.58-10.42]; p = 0.003)
exhibited a significantly shorter time to disease progres-
sion (Table 3). Therefore, one versus more than one met-
astatic site appeared superior in prediction for TTP on
second-line trastuzumab-based therapy and was included
into the multivariate model. Furthermore, patients
younger than 35 years derived less benefit from a second
trastuzumab-based treatment line (TTP median 3 months
[95% CI 0.23-5.77] versus 7 [95% CI 5.67-8.33]; 0.026)
(Table 3). In the multivariate model however, only one
versus more than one metastatic site was significantly
associated with TTP (p = 0.037, OR 1.91, 95% CI 0.25-
1.12) (Table 4).
None of the variables could independently predict for
response to second-line trastuzumab-based therapy in the
multinomial logistic regression model (Table 5).
One patient had brain metastases before initiation of anti-
body therapy, and thirty-nine (40.2%) developed brain
metastases either on second-line treatment or thereafter.
Median time to development of brain metastases was 21
months (95% CI 13.86-28.14), and overall survival fol-
lowing local treatment for brain metastases was 10
months (95% CI 4.53-15.47).
Twelve patients (30.8%) developed brain metastases in
less than one year. In this subgroup, early development of
brain metastases was significantly associated with the
presence of visceral metastases in a multinomial logistic
regression model (p = 0.012).
Table 1: Patient characteristics
Characteristics Patients
Entered n = 97
Median age (years) (range) 46 (25-73)
Age > 65 years 12 (12.4%)
Age < 35 years 8 (8.2%)
Stage 4 at primary diagnosis 24 (24.7%)
Grade 3 tumour 64 (66%)
Invasive ductal carcinoma 81 (83.5%)
Positive hormone receptor status 41 (42.3%)
Visceral metastases 73 (75.3%)
Median metastatic sites (sites) (range) 2 (1-6)
Lung 36
Liver 49
Bones 51
Lymph nodes 37
Soft tissue 48
Skin 16
Brain (before trastuzumab) 1
Others 3
More than one metastatic site 78 (80.4%)
Adjuvant chemotherapy 67 (69.1%)
Anthracyycline based 37
Taxane based 2
Combination anthracyclines/taxanes 22
Adjuvant endocrine therapy 26 (26.8%)
Adjuvant trastuzumab 9 (9.3%)
Duration adjuvant trastuzumab (median) (range) 10 (4-24)
Palliative treatment other than trastuzumab-based 35 (36.1%)
Second-line combination
Taxanes 21
Vinorelbine 30
Capecitabine 23
Gemcitabine 12
Anthracyclines 5
Others 6
Trastuzumab beyond second-line 55 (56.7%)
Lapatinib beyond second-line trastuzumab 14 (14.4%)
Table 1: Patient characteristics (Continued)BMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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OS in the entire population was 43 months (95% CI
37.92-48.09) (Figure 1). In the univariate analyses (log-
rank test), the following variables were significantly or
near significantly associated with shorter OS: Age younger
than 35 years (p = 0.023), hormone receptor negative dis-
ease (p = 0.075), more than one metastatic site (p =
0.003), more than two metastatic sites (p = 0.010), devel-
opment of brain metastases (p = 0.010) as well as early
development of brain metastases (p < 0.001) (Table 6). In
the Cox regression model, only early development of
brain metastases (p = 0.001) retained significance (Table
7).
Cardiac Toxicity
As outlined above, echocardiography was performed
every six months longest, with shorter intervals if indi-
cated. A significant drop in LVEF was observed in three
patients (3.1%); in one patient, trastuzumab had to be
stopped temporarily and in another discontinued perma-
nently due to symptomatic congestive heart failure (Table
2).
In none of the patients switched to lapatinib, a significant
drop in LVEF or congestive heart failure was observed.
Discussion
Concerning further therapy upon progression on trastuzu-
mab-based first-line treatment, two options are available:
Continuation of trastuzumab plus capecitabine, or a
switch to the tyrosine kinase inhibitor lapatinib, again in
combination with capecitabine. Both strategies are sup-
ported by data from prospective randomized phase III tri-
als [17,18], although a continuation of trastuzumab is
potentially less well established, as the trial conducted by
the German Breast Group (GBG-26) had to be closed early
due to poor accrual [17]. Still, given those results as well
Table 2: Efficacy endpoints
Endpoint Results
Median time to progression second-line trastuzumab-based therapy (months) 7 (95% CI 5.74-8.26)
Median time to progression first-line trastuzumab-based therapy (months) 8 (95% CI 6.26-9.74)
Overall survival (months) 43 (95% CI 37,92-48.09)
Response rate second-line trastuzumab-based therapy (%) 30.9%
Complete response (%) 7.2%
Partial response (%) 23.7%
Response rate first-line trastuzumab-based therapy (%) 44.3%
Complete response (%) 9.3%
Partial response (%) 35.1%
Clinical Benefit second-line trastuzumab-based therapy (%) 66%
Clinical Benefit first-line trastuzumab-based therapy (%) 83.5%
Time to development of brain metastases (months) 21 (95% CI 13.86-28.14)
Overall survival after treatment for brain metastases (months) 10 (95% CI 4.53-15.47)
Drop of left ventricular ejection fraction (LVEF) > 10% (n=) 3
Symptomatic congestive heart failure (n=) 2BMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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as data from a number of smaller studies, it is safe to
assume that there is a benefit from trastuzumab beyond
progression in a subset of patients. Therefore, identifying
this group in order to optimize palliative treatment for the
individual patient is important.
Our retrospective data again suggest that continuation of
trastuzumab is a valuable salvage option for patients with
advanced Her2-positive breast cancer, whose disease has
progressed on prior trastuzumab-based regimens. TTP on
trastuzumab-based second-line treatment was 7 months
Table 3: Univariate analysis: Influence on TTP (second-line)
Factor Median TTP (months) 95% CI SE* p =
Age > 65 years 6 vs. 7 0.00-12.79 3.36 n.s.
5.64-8.36 0.7
Age < 35 years 3 vs. 7 0.23-5.77 1.41 0.026
5.67-8.33 0.68
Stage 4 at diagnosis 6 vs. 7 5.52-8.48 0.76 n.s.
0.39-11.61 2.86
Grading (1,2 versus 3) 6 vs. 7 2.98-9.03 1.54 n.s.
5.6-8.41 0.72
Histologic type (ductal versus lobular) 6 vs. 9 4.86-7.14 0.58 n.s.
0.71-17.29 4.23
Positive hormone receptor status 6 vs. 7 4.64-7.36 0.7 n.s.
5.14-8.86 0.95
Time to recurrence < 12 months 6 vs. 7 3.41-8.59 1.32 n.s.
5.61-8.39 0.71
Visceral metastases 7 vs. 6 5.76-8.25 0.64 n.s.
0.00-12.53 3.33
Number of metastatic sites (1 versus 2) 14 vs. 6 9.56-18.44 2.26 0.013
5.02-6.98 0.5
Number of metastatic sites (2 versus > 2) 8 vs. 6 5.58-10.42 1.23 0.003
5.09-6.91 0.47
Trastuzumab from first-line palliative treatment 7 vs. 6 5.62-8.38 0.71 n.s.
4.65-7.35 0.69
Response to first-line trastuzumab-based therapy 7 vs. 6 5.25-8.75 0.89 n.s.
3.77-8.23 1.14
New metastatic sites at progression upon first-line trastuzumab-based therapy 7 vs. 6 4.81-9.19 1.12 n.s.
5.12-6.88 0.45
* SE: Standard error
Table 4: Cox proportional hazard model: Prediction of TTP 
(second-line)
Factor p = OR* 95% CI
Age < 35 years 0.097 0.53 1.04-3.5
Number of metastatic sites (1 versus 2) 0.037 1.91 0.25-1.12
* OR: Odds ratioBMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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median, and therefore not significantly different from the
first-line setting. Those data are well in line with results
from different other studies as well as the single phase III
trial. In those studies, a TTP of 6 - 8 months on second-
line trastuzumab-based therapy was reported [13-17].
OS in our population was 43 months. This is considerably
longer than survival reported in the pivotal trastuzumab
plus taxane trials [11,12], and might even hint at a sur-
vival-benefit associated with the use of trastuzumab in
multiple lines. Still, as this is a retrospective analysis, data
need to be interpreted with caution: Only patients who
had at least two lines of trastuzumab-based therapy were
included. Outcome for patients with rapid progression,
not eligible for second-line trastuzumab-based treatment,
therefore is not reported. This potential bias might well
add to the magnitude of the observed survival advantage.
Our study was initiated in order to identify readily availa-
ble clinical or histopathological factors potentially pre-
dicting for activity of trastuzumab treatment beyond
progression. Furthermore, we tried to establish risk factors
for early development of brain metastasis, as this sub-
group might derive the largest benefit from lapatinib due
to the fact that tyrosine-kinase inhibitors may pass an
intact blood-brain-barrier. In the trial conducted by Geyer
et al, this assumption was proven correct by the signifi-
cantly lower number of brain metastases observed in the
lapatinib group [18].
In the Cox regression model, only the number of meta-
static sites (one versus more than one) was significantly
associated with time to disease progression on second-
line trastuzumab-based therapy. Trastuzumab therefore
seemed to have higher activity in patients with a low
number of metastases. While this could indicate a higher
responsiveness of certain tumours to trastuzumab, it is
rather possible that this result would have been observed
with lapatinib or chemotherapy alone as well. In the
multinomial logistic regression model none of the factors
analysed predicted for response to second-line trastuzu-
mab-based therapy.
Therefore, readily available clinical and histopathological
features are not sufficient as decision-making tool, and
further exploration of mechanisms of resistance against
trastuzumab is warranted. Patients should be tested for
truncated Her2, as trastuzumab cannot bind to Her2-mol-
ecules lacking the extracellular domain [7]. Furthermore,
two recently presented studies suggested that tumours
with PTEN-loss and activated PI3-Kinase pathways may
be less responsive to trastuzumab [21,22].
Table 5: Multinomial logistic regression model: Prediction of Response (second-line)
Factor p = OR 95% CI
Age > 65 years 0.392 0.35 0.03-3.9
Age < 35 years 0.363 0.3 0.02-4
Stage 4 at diagnosis 0.839 1.11 0.4-3.14
Grading (1,2 versus 3) 0.268 0.37 0.06-2.15
Histologic type (ductal versus lobular) 0.19 0.17 0.01-2.41
Positive hormone receptor status 0.534 0.63 0.15-2.68
Time to recurrence < 12 months 0.332 0.43 0.08-2.36
Visceral metastases 0.147 3.96 0.62-25-35
Number of metastatic sites (1 versus 2) 0.318 0.36 0.05-2.64
Number of metastatic sites (2 versus > 2) 0.792 0.82 0.18-3.63
Trastuzumab from first-line palliative treatment 0.886 1.15 0.18-7.53
Response to fist-line trastuzumab-based therapy 0.201 2.58 0.6-11-08
New metastatic sites at progression upon first-line trastuzumab-based therapy 0.953 1.04 0.28-3.84BMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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As for overall survival, early development of brain metas-
tases predicted for inferior outcome. In a logistic regres-
sion model, development of brain metastases in less than
12 months was significantly associated with presence of
visceral metastases. This however is a feature of most
Her2-positive tumours, therefore, this subgroup awaits
further specification.
Conclusion
In conclusion, this retrospective analysis indicates that
trastuzumab has increased overall survival in Her2-posi-
tive patients. Furthermore, those results again suggest that
Table 6: Univariate analysis: Influence on OS
Factor Median TTP (months) 95% CI SE p =
Age > 65 years 44 vs. 43 29.77-58.23 7.26 n.s.
37.75-48.25 2.68
Age < 35 years 25 vs. 44 7.32-42.68 9.02 0.023
38.5-49.5 2.81
Stage 4 at diagnosis 43 vs. 39 37.74-48.26 2.69 n.s.
25.96-52.04 6.66
Grading (1,2 versus 3) 43 vs. 43 31.94-54.06 5.64 n.s.
37.38-48.72 2.92
Histologic type (ductal versus lobular) 43 vs. 52 38.35-47.65 2.37 n.s.
8.41-95.6 22.24
Positive hormone receptor status 47 vs. 39 38.4-55.61 4.39 0.075
31.95-46.05 5.6
Time to recurrence < 12 months 46 vs. 42 41.52-50.48 2.29 n.s.
35.7-48.3 3.21
Visceral metastases 40 vs. 53 33.82-46.18 3.16 n.s.
42-62 5.1
Number of metastatic sites (1 versus 2) NR* vs. 37 na§ na§ 0.003
27.35-46.65 4.92
Number of metastatic sites (2 versus > 2) 46 vs. 33 35.24-56.73 5.49 0.010
19.56-46.44 6.86
Trastuzumab from first-line palliative treatment 43 vs. 33 38.65-47.35 2.2 n.s.
9.02-57.98 12.75
Response to first-line trastuzumab-based therapy 46 vs. 42 36.33-55.67 4.94 n.s.
34.5-49.5 3.82
New metastatic sites at progression upon first-line trastuzumab-based therapy 44 vs. 42 26.05-61.96 9.16 n.s.
29.69-54.31 6.38
Development of brain metastases 33 vs. 46 32.81-43.19 2.9 0.010
40.32-51.69 5.2
Early development of brain metastases 19 vs. 44 9.11-28.89 2 < 0.001
40.07-47.93 5.05
* NR: Median OS not reached
§ na: Not available
Table 7: Cox proportional hazard model: Prediction of OS
Factor p = OR 95% CI
Age < 35 years 0.083 2.1 0.91-4.86
Positive hormone receptor status 0.075 0.61 0.36-1.05
Number of metastatic sites (1 versus 2) 0.053 4.2 1.74-1.01
Development of brain metastases 0.292 1.35 0.77-2.37
Early development of brain metastases 0.001 3.83 1.68-8.71BMC Cancer 2009, 9:367 http://www.biomedcentral.com/1471-2407/9/367
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a subgroup of patient may benefit from trastuzumab-
treatment in multiple lines. On the other hand, we were
not able to identify clinical or histopathological markers
predicting for activity of this approach. Therefore, identi-
fication of other biomarkers of trastuzumab resistance is
urgently warranted.
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